Introduction
Human blood groups were discovered over 100 years ago. During the course of the 20th century, a variety of different styles of terminology has been used to denote them. The International Society of Blood Transfusion (ISBT) established a Working Party in 1980 to devise a genetically based numerical terminology for red cell surface antigens. In 1990, the Working Party published a monograph describing a numerical terminology for 242 red cell antigens [1] . Another monograph listing 254 antigens was published in 1995 [2] and four brief updates have followed [3] [4] [5] [6] . In the 9 years since the 1995 report, many amendments to the classification have been necessary: 30 new antigens have been identified and six new systems created. Since 1995, the genes for nine blood group systems have been identified, so that sequenced genes for all 29 systems are now available. All blood group system genes have been located on a specific region of a chromosome ( Table 1) . The current classification can be found at www.iccbba.com/ppage107.htm.
The purpose of this monograph is to describe the ISBT terminology for red cell surface antigens and to tabulate the complete current version of the classification. Much of the information provided in the 1995 monograph [1] is reiterated here so that referral back will not generally be required, but only references published after 1995 are provided.
The ISBT numerical terminology
The mandate of the Committee is to provide a numerical terminology for red cell surface antigens. By definition, these antigens must be defined serologically by the use of a specific antibody. Numerical designations and blood group symbols cannot be allocated to nucleotide or amino acid sequences or polymorphisms, even though the presence of specific blood group antigens may be indicated by these techniques. All antigens receiving ISBT numbers must have been shown to be inherited characters.
All authenticated antigens fall into one of four classifications: systems; collections; low-incidence antigens (700 series); and high-incidence antigens (901 series). A blood group system consists of one or more antigens controlled at a single gene locus, or by two or more very closely linked homologous genes with little or no observable recombination between them. Each system has been shown to be genetically discrete from every other system. Collections consist of serologically, biochemically, or genetically related antigens, which do not fit the criteria required for system status. The 700 and 901 series contain low-and high-incidence antigens, respectively, which cannot be included in a system or collection.
Each antigen belonging to a blood group system is identified by a six-digit number (Tables 1-3 ). The first three digits represent the system (e.g. 006 for Kell) and the second three the specificity (e.g. 006003 for Kp a ). Alternatively, the system symbol followed by the antigen number may be used (e.g. KEL003 or, more usually, KEL3 as sinistral zeros may be removed). Phenotypes are represented by the system symbol, followed by a colon, followed by a list of antigens separated by commas. Those antigens shown to be absent are preceded by a minus sign (e.g. KEL: − 1,2, − 3,4). Genes are designated by the system symbol, followed by an asterisk, followed by the antigen number (e.g. KEL * 3 ). Genotypes have the system symbol, followed by an asterisk, followed by alleles or haplotypes separated by a slash (e.g. KEL * 2 , 3/2 , 4 ). Amorph or null genes are represented by a zero (e.g. KEL * 2 , 3/0 ). Gene and genotype designations are italicized (or underlined). Antigen, phenotype, gene and genotype designations for collections are constructed in the same way. For the 700 and 901 series, 700 or 901 replaces the system symbol.
Symbols for gene loci
The symbol for a gene or cluster of genes controlling a blood group system is the italicized symbol for the system (e.g. CO for the gene controlling the Colton system). The genes controlling all of the blood group systems have been cloned and, in many cases, the gene locus has an alternative symbol ( It is important to remember that when symbols such as RH*2 or MNS*10 are used, the symbol does not necessarily represent a single defined gene, but one of a cluster of genes or a hybrid of two genes.
A 'popular', alternative terminology
The numerical terminology was devised primarily for computer storage of information on blood group antigens and to provide a framework for a genetical classification. The numerical terminology is not suitable for everyday communication and many scientists working in the field of human blood groups prefer not to use it in publications. This has led to a variety of alternative names being used for some blood group antigens. In an attempt to introduce some uniformity, a recommended list of alternative names for antigens is provided in Table 3 . In most cases, the name or symbol is identical to that originally published, but in a few cases the more commonly used name is provided. In addition, there are recommended formats for describing phenotypes in the alternative terminology. These mostly employ traditional terminology, and examples are shown in Table 4 . A more complete list has been published previously [4] .
Blood group systems
There are currently 29 systems containing a total of 245 antigens (Tables 1 and 3 ). 
Modifications since 1995: existing systems

002, the MNS system
003, the P system
Evidence was presented suggesting that the same transferase encoded by A4GALT, is responsible for the biosynthesis of Table 9 ); *provisional. ) and altered expression of RH2 (C) and RH5 (e) [35] . A new terminology has been devised for epitopes of RH1 (D) [36] . Basically, each epitope has two numbers, one representing the conventional epD1 to epD9 system proposed by Lomas et al. [37] , the other representing subdivisions of those numbers. The complete numerical terminology for epD1 is 004001.001.001 (abbreviated to epD1.1) and the epD1 subsplit caused by DFR is 004001.001.002 (epD1.2). Partial D antigens will be designated by up to four upper case letters or Roman numerals on the line; for example DIIIa, DIV, DHAR, DFR.
005, the Lutheran system
Absence of a new Lutheran antigen of high incidence, LU21, is associated with homozygosity for an LU mutation encoding Asp94Glu [38] .
006, the Kell system
KEL25 (VLAN) and KEL28 (VONG) are low-incidence antigens associated with Arg248Gln and Arg248Trp, respectively, in the Kell glycoprotein [39, 40] . KEL26 (TOU) and KEL27 (RAZ) 
010, the Diego system
Seventeen new antigens have been added, all of low incidence and all associated with mutations in SLC4A1 encoding amino acid substitutions in the erythrocyte anion exchanger ( Table 5 ). The DI19 designation for Tr a is still provisional because only one case was analysed.
012, the Xg system
CD99, a glycoprotein encoded by a gene on both X and Y chromosomes, is recognized by monoclonal antibodies and human alloantibodies [54, 55] . MIC2, the structural gene for CD99, is closely linked to XG and shares substantial sequence homology with XG. Consequently, CD99 became XG2.
013, the Scianna system
Following the discovery that the Scianna antigens are expressed by the red cell adhesion protein, human ERMAP, expression of the low-incidence antigen, 700015 (Rd), was found to be associated with a mutation in ERMAP encoding Pro60Ala [9] . 700015 has become SC4. A new antigen of high incidence, STAR, is associated with Glu47Lys in ERMAP [56] and numbered SC5.
018, the Hh system
The system name has been changed to H.
020, the Gerbich system
A new antigen of low incidence, GEIS, associated with Thr32Asn in GPC and Thr11Asn in GPD [57] , has been numbered GE9.
021, the Cromer system
Three new antigens of high incidence have been added: CROM11 (GUTI) [58] , CROM12 (SERF) [59] , and CROM13 (ZENA) [60] are associated with Arg206His, Pro182Leu and His208Gln in CD55, respectively. [61] . KN4 (previously Sl a , now Sl1) requires Arg1601 on CD35, KN7 (previously Vil, now Sl2) requires Gly1601, and KN8 (Sl3) requires both Arg1601 and Ser1610 [61, 62] . The number KN8 is provisional because further complications are predicted.
022, the Knops system
Modifications since 1995: new systems
024, the Ok system
The high-incidence antigen OK1 (Ok a , previously 901006) became the sole antigen of the Ok system following identification of the gene (BSG) encoding the protein and of the amino acid substitution (Glu92Lys) responsible for the OK:−1 phenotype [12] .
025, the Raph system
This new system contains one antigen: RAPH1 (MER2, previously 901011). Distinction of RAPH from the other blood group systems was demonstrated by family studies and by the positioning of CD151, the controlling gene, at 11p15.5 [13 -15] .
026, the John Milton Hagen system
JMH1 (JMH, previously 901007) is carried on the semaphorin CD108 [16] . The gene encoding CD108, SEMA7A, is located on the long arm of chromosome 15 [17] , which distinguishes JMH1 from all existing blood group systems. JMH1 represents the antigen detected by antibodies produced by JMH:−1 individuals.
027, the I system
GCNT2, the gene encoding the N-acetylglucosaminyltransferase responsible for converting i-active straight chains to I-active branched chains, has been cloned and some mutations responsible for the i adult phenotype identified [18, 19] . I1 antigen (I, previously 207001) is the only antigen of the I system. The i antigen, the precursor of I1, provisionally remains as 207002.
028, the Globoside system
The gene (B3GALT3) encoding the N-acetylgalactosaminyltransferase (globoside synthase) responsible for converting P k (209002) to P (previously 209001, globoside) has been cloned and inactivating mutations responsible for the P k (Pnegative) phenotype have been identified [20, 21] . P has become GLOB1, the only antigen of the Globoside system.
029, the GIL system
GIL1, the only antigen of the GIL system, is an antigen of high incidence located on the glycerol transporter aquaporin 3, and the GIL:−1 phenotype results from an inactivating mutation within the AQP3 gene [22, 23] . AQP3 is on chromosome 9p13, so GIL is genetically discrete from all other blood group systems.
Guidelines for the establishment of new blood group systems
For an antigen to form a new blood group system it must be defined by a human alloantibody, be an inherited character, the gene encoding it must have been identified and sequenced, and its chromosomal location must be known. In addition, the gene must be different from, and not a closely linked homologue of, all other genes encoding antigens of existing blood group systems. All established blood group systems meet these criteria.
Guidelines for the inclusion of a new specificity in an established system
All antigens awarded an ISBT number must have been shown to be inherited, and at least one of the following four criteria must be met.
(1) An antithetical relationship between a new antigen and one already assigned to the system.
(2) Demonstration that expression of the antigen is associated with a variation in the nucleotide sequence of the gene controlling the system.
(3) Evidence, from a linkage analysis of family data, that the controlling allele is probably a newly recognized form of the pertinent gene, and supporting serological or biochemical information.
(4) Demonstration that an antigen is located on a protein or glycoprotein that carries other antigens belonging to the system. It must be remembered, however, that this could result from post-translational modification of a gene product, such as glycosylation, which would not support inclusion within the system.
Blood group collections
There are six blood group collections (Table 6) .
A new Collection, 211 or Vel, was created to include two serologically related antigens of high incidence, Vel (VEL1, previously 901001) and ABTI (VEL2, previously 901015) [63, 64] .
An antibody produced by a patient with ER:−1,−2 red cells and with the characteristics of antibodies of the ER Collection reacted with ER:1,−2, ER:−1,2, and the only other example of ER:−1,−2 red cells [65] . The antigen recognized by this antibody has become ER3 (208003) of the ER Collection.
Since 1995, 207001 (I1, I) has formed the I system and retains the symbol I1, and 209001 (GLOB1, P) has formed the Globoside system and retains the symbol GLOB1. The creation of the I and Globoside systems means that these two systems have identical symbols, I and GLOB, to those of Collections 207 and 209. This should not cause confusion, however, as I1 and GLOB1 cannot refer to 207001 and 209001, as those numbers are now obsolete. Collection 207 now contains only one antigen. These anomalies will be resolved when a separate carbohydrate collection is created.
series, low-incidence antigens
There are currently 19 antigens in the 700 series (Table 7) . Since 1995, no new numbers have been added and 18 numbers have been made obsolete: 16 antigens have joined the Diego system (Table 5) ; 700015 (Rd) has become SC4; and 700053 (LOCR) has become RH55.
Criteria for inclusion in the 700 series:
(1) An incidence of < 1% in most populations tested.
(2) Distinction from all other numbered low-incidence antigens of the 700 series as well as those of the blood group systems and collections.
(3) Demonstration of inheritance through at least two generations.
series, high-incidence antigens
There are currently nine antigens in the 901 series (Table 8) . Since 1995, two new antigens, both of high incidence, have been added: 901015 (ABTI) [63] and 901016 (MAM) [66] , although 901015 (ABTI) has now become VEL2 of the 211 collection. Three antigens became the sole antigens of new blood group systems and their 901 numbers are obsolete: 901006 (Ok a ) has become OK1; 901007 (JMH) has become JMH1; and 901011 (MER2) has become RAPH1 ( Table 1) .
The gene encoding the β1,4-N-acetylgalactosaminyltransferase responsible for 901012 (Sd a ) antigen has been cloned [67, 68] , but 901012 has not formed a new blood group system because the molecular basis for the Sd a polymorphism has not been determined.
Criteria for inclusion in the 901 series:
(1) An incidence of > 90% in most populations tested.
(2) Distinction from all other numbered high-incidence specificities.
(3) Demonstration that the antigen is lacking from the red cells of at least 2 sibs, i.e. that the negative phenotype is genetically determined.
Obsolete numbers
There is no recycling of blood group numbers: once a number has been allocated to a specificity, that number cannot be subsequently used for any other specificity. Consequently, if the number of a specificity becomes inappropriate, then that number becomes obsolete. Obsolete numbers are listed in Table 9 .
Procurement of ISBT numerical designations
Choice of symbol
Symbols for designations of new specificities will consist of three to six on-line capital letters and must not duplicate, alphabetically or phonetically, any current or obsolete symbols shown in the tables. Also, symbols used in related fields, such as those used for platelet and leucocyte antigens, must be avoided. Symbols for specificities that may herald new blood group systems, and thus new genes, have the further constraint that they must differ from any symbols given to genes by the HUGO Nomenclature Committee (http://www. gene.ucl.ac.uk/nomenclature/).
Procedures for acquisition of an ISBT number
The initial stipulation is that materials for defining the new specificity should be available for either circulation or inhouse testing; the futility of defining a new specificity from which future new specificities cannot be distinguished is obvious. Proposals should be submitted with supporting data to the members of the Committee listed below, who are authorized to allocate numbers provisionally in consultation with the Chair. All decisions must be ratified by the Committee before being finalized.
• For a new blood group system or collection: Dr Geoff Daniels.
• For a specificity number within an established system: Dr Marion Reid for the MNS system; Dr Sylvano Wendel or Mrs Marilyn Moulds for the Rh system; Dr Jan Jørgensen for other systems.
• For a specificity number in a current collection: Dr Geoff Daniels.
• For a 700 number: Dr Teresa Zelinski.
• For a 901 number: Dr Geoff Daniels. 
Conclusions
Although the primary function of the Committee is to monitor and update the terminology, there are two main issues that need to be tackled in the future: updating and redefining the terminology for blood group genes and alleles; and devising a collection for those carbohydrate antigens that do not belong to a system. The Committee strongly urges that all authors in the field of human red cell blood groups should use the terminology provided in Tables 1-8 ). For clarity, it is often advisable when using the more traditional terminology to include the ISBT terminology in parentheses, for example An a (GE7).
All members of the Committee, listed in Appendix I, are prepared to handle requests for advice or assistance in any aspect of an investigation or to direct them to the most appropriate authority. The Chair of the Committee would be happy to receive any comments or criticisms of the terminology and would raise them at a Committee meeting. Membership of the Committee is open to colleagues who are considered 
